Impact of turnaround time (TAT) of molecular testing on initial treatment (Tx) in newly diagnosed stage 4 non-small cell lung cancer (NSCLC 4): An Integra Connect (IC) retrospective observational study

MLA

Mike Gart, et al. “Impact of Turnaround Time (TAT) of Molecular Testing on Initial Treatment (Tx) in Newly Diagnosed Stage 4 Non-Small Cell Lung Cancer (NSCLC 4): An Integra Connect (IC) Retrospective Observational Study.” Journal of Clinical Oncology, vol. 40, June 2022, p. e13510. EBSCOhost, https://doi.org/10.1200/jco.2022.40.16_suppl.e13510.

APA

Mike Gart, Lucio N. Gordan, Rushir J. Choksi, Daniel P. Petro, Jeffrey A. Scott, Prateesh Varughese, Erin Alwon, & Robert E. Smith. (2022). Impact of turnaround time (TAT) of molecular testing on initial treatment (Tx) in newly diagnosed stage 4 non-small cell lung cancer (NSCLC 4): An Integra Connect (IC) retrospective observational study. Journal of Clinical Oncology, 40, e13510. https://doi.org/10.1200/jco.2022.40.16_suppl.e13510

Chicago

Mike Gart, Lucio N. Gordan, Rushir J. Choksi, Daniel P. Petro, Jeffrey A. Scott, Prateesh Varughese, Erin Alwon, and Robert E. Smith. 2022. “Impact of Turnaround Time (TAT) of Molecular Testing on Initial Treatment (Tx) in Newly Diagnosed Stage 4 Non-Small Cell Lung Cancer (NSCLC 4): An Integra Connect (IC) Retrospective Observational Study.” Journal of Clinical Oncology 40 (June): e13510. doi:10.1200/jco.2022.40.16_suppl.e13510.